Antineoplastic agent, Tyrosine kinase inhibitor Medicines in UAE
144 medicines available
About Antineoplastic agent, Tyrosine kinase inhibitor Medicines
This page lists all Antineoplastic agent, Tyrosine kinase inhibitor medicines available in UAE pharmacies.
Click on any medicine name to view detailed information including uses, dosage, side effects, and availability.
Complete List of Antineoplastic agent, Tyrosine kinase inhibitor Medicines
Class: | Bruton's tyrosine kinase (BTK) inhibitor
Use: | Treatment of adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL); also indicated for mantle cell lymp...
Class: | Bruton's tyrosine kinase (BTK) inhibitor
Use: | Treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and for the treatment of adult patie...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of chronic myeloid leukemia (CML) in adults with Philadelphia chromosome-positive (Ph+) CML who have had prior therapy and are resistant or intole...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult patients with chronic myeloid leukemia (CML) in chronic phase with the Philadelphia chromosome-positive (Ph+) mutation, particularly in t...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adults with unresectable or metastatic gastrointestinal stromal tumors (GISTs) with a mutation in the KIT gene, specifically for those with PDG...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of advanced renal cell carcinoma (RCC) after one prior therapy
Adult dose: | Initial dose of 5 mg taken orally twice daily; may be adjusted base...
Class:| Tyrosine kinase inhibitor
Use:| Treatment of adult patients with chronic myeloid leukemia (CML)
Adult dose:| 400 mg orally once daily with food; dose adjustments may be required based on r...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of chronic myelogenous leukemia (CML) in adults with resistance or intolerance to prior therapy
Adult dose: | Initial dose is 500 mg once daily;...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of chronic myelogenous leukemia (CML) in adults with Philadelphia chromosome-positive (Ph+) disease
Adult dose: | Initial dose of 500 mg once da...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of chronic myelogenous leukemia (CML) in adults with resistance or intolerance to prior therapy
Adult dose: | 400 mg orally once daily, with or ...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of chronic myeloid leukemia (CML) in adults with Philadelphia chromosome-positive (Ph+) disease, particularly in patients who are resistant or int...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC)
Adult dose: | 20 mg orally once daily, taken at the same time each day...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC)
Adult dose: | 60 mg orally once daily; may be adjusted based on tolera...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) in patients who have progressed on or are intolerant to crizotinib
Adult dose: | 4...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations
Adult dose: | 45 mg orally once daily; may be reduced to 30 mg or ...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations
Adult dose: | 30 mg orally once daily, taken continuously until di...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult and pediatric patients with solid tumors that are ROS1-positive or NTRK-positive, including non-small cell lung cancer (NSCLC) and other ...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult and pediatric patients with solid tumors that are positive for NTRK gene fusions, ROS1-positive non-small cell lung cancer (NSCLC), and o...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult and pediatric patients with solid tumors that are positive for NTRK gene fusions, ROS1-positive non-small cell lung cancer (NSCLC), and o...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer
Adult dose: | 150 mg orally once daily, taken at least 1 hour before or 2 hours afte...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer
Adult dose: | 150 mg orally once daily, taken at least 1 hour before or 2 hours afte...
Class: | Spleen tyrosine kinase (SYK) inhibitor
Use: | Treatment of chronic immune thrombocytopenic purpura (ITP) in adults who have had an insufficient response to other treatments
Adult dose: | ...
Class: | Spleen tyrosine kinase (SYK) inhibitor
Use: | Treatment of chronic immune thrombocytopenic purpura (ITP) in adults who have had an insufficient response to other treatments
Adult dose: | ...
Class: | Spleen tyrosine kinase (SYK) inhibitor
Use: | Treatment of chronic immune thrombocytopenia (ITP) in adults who have had an insufficient response to previous treatments
Adult dose: | 100 m...